Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer. 2001 Nov 15; 92(10):2501-7.